Venrock Healthcare Capital Partners XP, L.P. has made headlines with its latest filing, revealing substantial ownership stakes in Lycia Therapeutics, Inc. This move underscores the firm's commitment to the healthcare sector, particularly in the biological products industry.
On October 22, 2026, Venrock Healthcare Capital Partners XP, L.P. filed a Form 3 with the SEC, detailing its ownership in Lycia Therapeutics, a company focused on developing innovative solutions in biological products. This filing is significant as it highlights the growing interest from investment firms in the healthcare sector, particularly in companies that are pioneering advancements in biological therapies.
Background
Venrock Healthcare Capital Partners XP, L.P. is a Delaware-based investment firm focused on healthcare investments. The firm is part of Venrock, a well-established venture capital firm that has been active in the healthcare space for many years. Venrock Healthcare Capital Partners XP is known for its strategic investments in companies that are shaping the future of healthcare.
According to the recent filings, Venrock Healthcare Capital Partners XP, L.P. has been actively involved in the healthcare investment landscape. The firm’s previous filings include a Form D submitted on November 20, 2024, indicating ongoing activities in raising capital for healthcare ventures.
What the Filing Says
The recent SEC filing reveals that Venrock Healthcare Capital Partners XP, L.P. holds significant shares in Lycia Therapeutics, Inc. Specifically, the filing indicates that the firm is a ten percent owner of the company. This ownership is classified as indirect, as it is held through various funds managed by Venrock.
Notably, the filing outlines that Venrock Healthcare Capital Partners III, L.P., along with other affiliated entities, collectively own a substantial number of shares in Lycia, which includes both Series C and Series D Preferred Stock convertible into common stock. The filing states, "Each share of Series C Preferred Stock and Series D Preferred Stock is convertible into Common Stock on a one-for-0.221793422 basis at the option of the holder." This strategic move positions Venrock to benefit from potential growth in Lycia's stock value as the company progresses.
Impact
This significant ownership stake by Venrock Healthcare Capital Partners XP, L.P. may influence various stakeholders, including other investors, competitors, and the broader healthcare industry. As Venrock continues to invest in innovative companies like Lycia Therapeutics, it may drive competition and innovation within the biological products sector.
Additionally, the filing indicates that several individuals and entities, including Koh Bong Y and Shah Nimish P, are also reporting owners with significant stakes in Lycia. Their involvement suggests a strong alignment of interests among key players within Venrock, potentially leading to strategic decisions that could impact Lycia's future direction.
What's Next
The filing does not specify what happens next for Venrock Healthcare Capital Partners XP, L.P. or Lycia Therapeutics, Inc. However, the increased ownership may lead to further developments in their partnership, including potential collaborations or additional investments.
As the healthcare landscape continues to evolve, Venrock's strategic investments will likely play a crucial role in shaping the future of biological products and therapies.